Table 5.
Clinical and pathological characteristics of 71 patients in the validation cohort
| Characteristic | Sensitive (n = 56) | Resistant (n = 15) | P |
|---|---|---|---|
| FIGO stage | |||
| I | 3 | 0 | 0.630 |
| II | 7 | 3 | |
| III | 42 | 10 | |
| IV | 4 | 2 | |
| Histological type | |||
| Serous | 38 | 11 | 0.533 |
| Clear cell | 10 | 1 | |
| Other | 8 | 3 | |
| Mimitin expression | |||
| Low | 9 | 10 | <0.001 |
| High | 47 | 5 | |
| 14-3-3 ζ/δ expression | |||
| Low | 7 | 11 | <0.001 |
| High | 49 | 4 | |
| PFS (median, months) | 20 | 4 | <0.001 |
| OS (median, months) | 31 | 11 | <0.001 |
Significant values appear in boldface type. P < 0.05 was considered to be statistically significant. OS, overall survival; PFS, progression-free survival.